close 77% jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. Hinnavahelepingud on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 77% jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Palume teil kaaluda, kas hinnavahelepingute süsteem on teile arusaadav ja kas olete valmis võtma riski, mis suure tõenäoususega on kahjumlik.
Change languageEesti
Dashboard

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Kodu・Aktsiate loetelu・ReShape Lifesciences Inc
Search

ReShape Lifesciences Inc

Avatud

2.51 0.8

Hinna uuendus 5. aug 2025, 19:49 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.45

Max

2.54

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

13. aug 2025

ReShape Lifesciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. aug 2025, 21:42 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

DJ

Loe

4. aug 2025, 21:21 UTC

Tulu
Suurimad hinnamuutused turgudel

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

DJ

Loe

4. aug 2025, 20:45 UTC

Tulu

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

DJ

Loe

4. aug 2025, 19:15 UTC

Suurimad hinnamuutused turgudel

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

DJ

Loe

4. aug 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Loe

4. aug 2025, 23:41 UTC

Market Talk

Nikkei May Rise on Fed Stimulus Hopes

DJ

Loe

4. aug 2025, 23:28 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Loe

4. aug 2025, 23:28 UTC

Market Talk

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

DJ

Loe

4. aug 2025, 21:30 UTC

Tulu

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

DJ

Loe

4. aug 2025, 21:21 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

DJ

Loe

4. aug 2025, 21:18 UTC

Tulu

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

DJ

Loe

4. aug 2025, 20:25 UTC

Market Talk

India Hits Back Over Russian Oil Purchases -- Market Talk

DJ

Loe

4. aug 2025, 20:25 UTC

Tulu

Transocean 2Q Loss $938M >RIG

DJ

Loe

4. aug 2025, 20:25 UTC

Tulu

Transocean 2Q Loss/Shr $1.06 >RIG

DJ

Loe

4. aug 2025, 20:18 UTC

Tulu

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

DJ

Loe

4. aug 2025, 20:15 UTC

Tulu

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

DJ

Loe

4. aug 2025, 20:14 UTC

Tulu

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

DJ

Loe

4. aug 2025, 20:14 UTC

Tulu

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

DJ

Loe

4. aug 2025, 20:14 UTC

Tulu

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

DJ

Loe

4. aug 2025, 20:13 UTC

Tulu

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

DJ

Loe

4. aug 2025, 20:09 UTC

Tulu

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

DJ

Loe

4. aug 2025, 20:06 UTC

Tulu

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

DJ

Loe

4. aug 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

DJ

Loe

4. aug 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

DJ

Loe

4. aug 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

DJ

Loe

4. aug 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

DJ

Loe

4. aug 2025, 19:41 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

DJ

Loe

4. aug 2025, 19:28 UTC

Market Talk

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

DJ

Loe

4. aug 2025, 19:07 UTC

Market Talk

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

DJ

Loe

4. aug 2025, 18:27 UTC

Market Talk

Gold Climbs on Rate Cut Speculation -- Market Talk

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

ReShape Lifesciences Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

0

Osta

0

Hoia

0

Müü

Põhineb 0 analüütiku instrumendi ReShape Lifesciences Inc aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

$

Muud aktsiad sektorist

JNJ

Johnson and Johnson

170.73

↓-0.23%

NVS

Novartis AG

117.78

↓-0.02%

ABT

Abbott Laboratories

130.77

↑ +0.52%

TMO

Thermo Fisher Scientific Inc

466.56

↓-0.22%

ISRG

Intuitive Surgical Inc

476.87

↓-1.3%